News >

Expert Highlights Latest Immunotherapy Efforts in CRC

Brandon Scalea
Published: Thursday, Aug 23, 2018

Michael J. Overman, MD

Michael J. Overman, MD
The role of checkpoint inhibitors in regulating host immune response to cancer has provided practice-changing therapeutic targets for clinicians. This has significantly shaped the treatment landscape in colorectal cancer (CRC), but much work remains for certain subtypes, particularly the microsatellite stable (MSS) patient population, said Michael J. Overman, MD.

, Overman, an associate professor in the Department of Gastrointestinal Medical Oncology at The University of Texas MD Anderson Cancer Center, discussed the current state of immunotherapy in patients with CRC and how to optimally manage immune-related adverse events.

OncLive: How has the rise of immunotherapy impacted patients with CRC?

Overman: Fundamentally, we've identified a subset within colon cancer that is very immune-responsive. For that subset, we have generated 3 different approvals for immunotherapy. In part, this was based on nonrandomized studies because for that subset, this kind of treatment works tremendously well. It's been a real success because, generally, we give therapy to everyone and it works in a small fraction of people. That has sort of been the normal cancer paradigm.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication